CSPG4: a prototype oncoantigen for translational immunotherapy studies
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CSPG4: a prototype oncoantigen for translational immunotherapy studies
Authors
Keywords
Chondroitin sulfate proteoglycan-4 (CSPG4), Cancer immunotherapy, Comparative oncology, DNA vaccination
Journal
Journal of Translational Medicine
Volume 15, Issue 1, Pages -
Publisher
Springer Nature
Online
2017-07-01
DOI
10.1186/s12967-017-1250-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chimeric antigen receptor T cell therapy: 25years in the making
- (2016) Saar Gill et al. BLOOD REVIEWS
- Cancer immunotherapy: the beginning of the end of cancer?
- (2016) Sofia Farkona et al. BMC Medicine
- Combining a chimeric antigen receptor and a conventional T-cell receptor to generate T cells expressing two additional receptors (TETARs) for a multi-hit immunotherapy of melanoma
- (2016) Ugur Uslu et al. EXPERIMENTAL DERMATOLOGY
- A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein
- (2016) Manal Amoury et al. INTERNATIONAL JOURNAL OF CANCER
- Prolongation of survival of dogs with oral malignant melanoma treated by en bloc surgical resection and adjuvant CSPG4-antigen electrovaccination
- (2016) L. A. Piras et al. Veterinary and Comparative Oncology
- Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors
- (2015) Yangyang Wang et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Proteome characterization of melanoma exosomes reveals a specific signature for metastatic cell lines
- (2015) Ikrame Lazar et al. Pigment Cell & Melanoma Research
- New developments in the management of advanced melanoma – role of pembrolizumab
- (2015) Giuseppina Improta et al. OncoTargets and Therapy
- Theranostic Impact of NG2/CSPG4 Proteoglycan in Cancer
- (2015) Pier Andrea Nicolosi et al. Theranostics
- Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival
- (2015) Aurelie Poli et al. Oncotarget
- The importance of comparative oncology in translational medicine
- (2014) Federica Riccardo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CSPG4-Specific Immunity and Survival Prolongation in Dogs with Oral Malignant Melanoma Immunized with Human CSPG4 DNA
- (2014) F. Riccardo et al. CLINICAL CANCER RESEARCH
- Xenogene vaccination in the therapy of cancer
- (2014) Federica Cavallo et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Mechanisms of tumor escape from immune system: Role of mesenchymal stromal cells
- (2014) Alessandro Poggi et al. IMMUNOLOGY LETTERS
- Chondroitin Sulfate Proteoglycan CSPG4 as a Novel Hypoxia-Sensitive Marker in Pancreatic Tumors
- (2014) Shereen Keleg et al. PLoS One
- Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells
- (2014) Rachel E Beard et al. Journal for ImmunoTherapy of Cancer
- High chondroitin sulfate proteoglycan 4 expression correlates with poor outcome in patients with breast cancer
- (2013) Nicholas C. Hsu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- T Lymphocytes Redirected against the Chondroitin Sulfate Proteoglycan-4 Control the Growth of Multiple Solid Tumors both In Vitro and In Vivo
- (2013) C. Geldres et al. CLINICAL CANCER RESEARCH
- Vaccination With ENO1 DNA Prolongs Survival of Genetically Engineered Mice With Pancreatic Cancer
- (2013) Paola Cappello et al. GASTROENTEROLOGY
- Kinetics of Tumor Destruction by Chimeric Antigen Receptor-modified T Cells
- (2013) Usanarat Anurathapan et al. MOLECULAR THERAPY
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Xenogeneic Human p53 DNA Vaccination by Electroporation Breaks Immune Tolerance to Control Murine Tumors Expressing Mouse p53
- (2013) Ruey-Shyang Soong et al. PLoS One
- A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma
- (2013) J. M. Ottnod et al. Veterinary and Comparative Oncology
- Assessment of bone marrow infiltration diagnosed by flow cytometry in canine large B cell lymphoma: Prognostic significance and proposal of a cut-off value
- (2013) Laura Marconato et al. VETERINARY JOURNAL
- NG2/CSPG4-collagen type VI interplays putatively involved in the microenvironmental control of tumour engraftment and local expansion
- (2013) S. Cattaruzza et al. Journal of Molecular Cell Biology
- Trial watch
- (2013) Laura Senovilla et al. OncoImmunology
- Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers
- (2013) Cristina Marchini et al. Frontiers in Oncology
- A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors
- (2012) Maddalena Arigoni et al. ANGIOGENESIS
- CSPG4 as a Target of Antibody-Based Immunotherapy for Malignant Mesothelioma
- (2012) Z. Rivera et al. CLINICAL CANCER RESEARCH
- PDGFs and PDGFRs in canine osteosarcoma: New targets for innovative therapeutic strategies in comparative oncology
- (2012) Lorella Maniscalco et al. VETERINARY JOURNAL
- Harnessing DNA-induced immune responses for improving cancer vaccines
- (2012) Andrés A. Herrada et al. Human Vaccines & Immunotherapeutics
- DNA vaccination against oncoantigens
- (2012) Manuela Iezzi et al. OncoImmunology
- Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma
- (2011) Agnete Svendsen et al. ACTA NEUROPATHOLOGICA
- Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor
- (2011) Deborah A. Grosenbaugh et al. AMERICAN JOURNAL OF VETERINARY RESEARCH
- 2011: the immune hallmarks of cancer
- (2011) Federica Cavallo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Exosomes Released by Melanoma Cells Prepare Sentinel Lymph Nodes for Tumor Metastasis
- (2011) J. L. Hood et al. CANCER RESEARCH
- The CSPG4-specific monoclonal antibody enhances and prolongs the effects of the BRAF inhibitor in melanoma cells
- (2011) Ling Yu et al. IMMUNOLOGIC RESEARCH
- Redirected Lysis of Human Melanoma Cells by a MCSP/CD3-bispecific BiTE Antibody That Engages Patient-derived T Cells
- (2011) Hitoe Torisu-Itakura et al. JOURNAL OF IMMUNOTHERAPY
- CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma
- (2011) Matthew A. Price et al. Pigment Cell & Melanoma Research
- Targeting the NG2/CSPG4 Proteoglycan Retards Tumour Growth and Angiogenesis in Preclinical Models of GBM and Melanoma
- (2011) Jian Wang et al. PLoS One
- Eradication of melanomas by targeted elimination of a minor subset of tumor cells
- (2011) P. Schmidt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- LUPA: A European initiative taking advantage of the canine genome architecture for unravelling complex disorders in both human and dogs
- (2011) Anne-Sophie Lequarré et al. VETERINARY JOURNAL
- Chondroitin sulfate proteoglycan-4: A biomarker and a potential immunotherapeutic target for canine malignant melanoma
- (2011) Saray Lorda Mayayo et al. VETERINARY JOURNAL
- Transmembrane Signaling Proteoglycans
- (2010) John R. Couchman Annual Review of Cell and Developmental Biology
- Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen
- (2010) Claudia Bluemel et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A High Molecular Weight Melanoma-Associated Antigen-Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
- (2010) W. R. Burns et al. CANCER RESEARCH
- A Better Immune Reaction to Erbb-2 Tumors Is Elicited in Mice by DNA Vaccines Encoding Rat/Human Chimeric Proteins
- (2010) Elena Quaglino et al. CANCER RESEARCH
- CSPG4 in Cancer: Multiple Roles
- (2010) X. Wang et al. CURRENT MOLECULAR MEDICINE
- DNA vaccines against cancer come of age
- (2010) Freda K Stevenson et al. CURRENT OPINION IN IMMUNOLOGY
- Pericyte deficiencies lead to aberrant tumor vascularizaton in the brain of the NG2 null mouse
- (2010) Feng-Ju Huang et al. DEVELOPMENTAL BIOLOGY
- CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer
- (2010) Xinhui Wang et al. JNCI-Journal of the National Cancer Institute
- Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo
- (2010) Marco de Bruyn et al. Molecular Cancer
- Biology, diagnosis and treatment of canine appendicular osteosarcoma: Similarities and differences with human osteosarcoma
- (2010) Emanuela Morello et al. VETERINARY JOURNAL
- The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research
- (2009) M. A. Cheever et al. CLINICAL CANCER RESEARCH
- Human bone marrow mesenchymal cells express NG2: possible increase in discriminative ability of flow cytometry during mesenchymal stromal cell identification
- (2009) Ilknur Kozanoglu et al. CYTOTHERAPY
- A comprehensive catalogue of somatic mutations from a human cancer genome
- (2009) Erin D. Pleasance et al. NATURE
- Gene Expression Profiles of Sporadic Canine Hemangiosarcoma Are Uniquely Associated with Breed
- (2009) Beth A. Tamburini et al. PLoS One
- NG2, a novel proapoptotic receptor, opposes integrin α4 to mediate anoikis through PKCα-dependent suppression of FAK phosphorylation
- (2008) N E Joo et al. CELL DEATH AND DIFFERENTIATION
- Melanoma-associated chondroitin sulphate proteoglycan as a new target antigen for CD4+T cells in melanoma patients
- (2008) Cornelia Erfurt et al. INTERNATIONAL JOURNAL OF CANCER
- Interaction of Syntenin-1 and the NG2 Proteoglycan in Migratory Oligodendrocyte Precursor Cells
- (2008) Nivedita Chatterjee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling
- (2008) M Chekenya et al. ONCOGENE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started